One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Comprehensive Cardiovascular Magnetic Resonance Tissue Characterization and Cardiotoxicity in Women With Breast Cancer
Paaladinesh Thavendiranathan, MD, SM1,2; Tamar Shalmon, MD1,2; Chun-Po Steve Fan, PhD3; Christian Houbois, MD2,4; Eitan Amir, MD, PhD5; Yobiga Thevakumaran, RN1; Emily Somerset, MSc3; Julia M. Malowany, MSc6; Camila Urzua-Fresno, MD1,2; Paul Yip, PhD7; Chris McIntosh, PhD2,4,8,9,10,11; Marshall S. Sussman, PhD2,4; Christine Brezden-Masley, MD, PhD12; Andrew T. Yan, MD13; C. Anne Koch, MD, PhD14; Neil Spiller, BA2; Husam Abdel-Qadir, MD, PhD1,15; Coleen Power, NP, MN, MPH1; Kate Hanneman, MD, MPH2,4; Bernd J. Wintersperger, MD2,4
doi : 10.1001/jamacardio.2023.0494
June 2023, Vol 8, No. 6, Pages 518-623
Importance There is a growing interest in understanding whether cardiovascular magnetic resonance (CMR) myocardial tissue characterization helps identify risk of cancer therapy–related cardiac dysfunction (CTRCD).
Aspirin vs Clopidogrel for Long-term Maintenance After Coronary Stenting in Patients With Diabetes
Tae-Min Rhee, MD1; Jang-Whan Bae, MD2; Kyung Woo Park, MD1; Seung-Woon Rha, MD3; Jeehoon Kang, MD1; Heesun Lee, MD4; Han-Mo Yang, MD1; Soo-Heon Kwak1; In-Ho Chae, MD5; Won-Yong Shin, MD6; Dae-Kyeong Kim, MD7; Ju Hyeon Oh, MD8; Myung Ho Jeong, MD9; Yong Hoon Kim, MD10; Nam Ho Lee, MD11; Seung-Ho Hur, MD12; Junghan Yoon, MD13; Jung-Kyu Han, MD1; Eun-Seok Shin, MD14; Bon-Kwon Koo, MD1; Hyo-Soo Kim, MD1; for the HOST-EXAM Investigators
doi : 10.1001/jamacardio.2023.0592
Importance Selecting the optimal antiplatelet agent in patients who have received percutaneous coronary intervention is especially important in those with diabetes due to the heightened risk of ischemic events in this population. Studies on the efficacy and safety of clopidogrel vs aspirin for long-term maintenance after percutaneous coronary intervention in patients with diabetes are lacking.
Quality of Care and Clinical Outcomes for Patients With Heart Failure at Hospitals Caring for a High Proportion of Black Adults
Jamie Diamond, MD, MPH1; Iyanuoluwa Ayodele, MS2; Gregg C. Fonarow, MD3; Karen E. Joynt-Maddox, MD, MPH4; Robert W. Yeh, MD5; Gmerice Hammond, MD, MPH4; Larry A. Allen, MD, MHS6; Stephen J. Greene, MD1,2; Karen Chiswell, PhD2; Adam D. DeVore, MD, MHS1,2; Clyde Yancy, MD7; Rishi K. Wadhera, MD, MPP, MPhil5
doi : 10.1001/jamacardio.2023.0695
Importance Black adults with heart failure (HF) disproportionately experience higher population-level mortality than White adults with HF. Whether quality of care for HF differs at hospitals with high proportions of Black patients compared with other hospitals is unknown.
Effect of Dapagliflozin on Total Heart Failure Events in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction
Pardeep S. Jhund, MBChB, MSc, PhD1; Brian L. Claggett, PhD2; Atefeh Talebi, PhD1; Jawad H. Butt, MD1; Samvel B. Gasparyan, PhD3; Lee-Jen Wei, PhD4; Zachary R. McCaw, PhD5; Ulrica Wilderäng, PhD3; Olof Bengtsson, PhLic3; Akshay S. Desai, MD, MPH2; Magnus Petersson, MD, PhD3; Anna Maria Langkilde, MD, PhD3; Rudolf A. de Boer, MD, PhD6; Adrian F. Hernandez, MD7,8; Silvio E. Inzucchi, MD9; Mikhail N. Kosiborod, MD10; Carolyn S. P. Lam, MD11; Felipe A. Martinez, MD12; Sanjiv J. Shah, MD13; Muthiah Vaduganathan, MD, MPH2; Scott D. Solomon, MD2; John J. V. McMurray, MD1
doi : 10.1001/jamacardio.2023.0711
Importance In the Dapagliflozin Evaluation to Improve the Lives of Patients With Preserved Ejection Fraction Heart Failure (DELIVER) trial, dapagliflozin reduced the risk of time to first worsening heart failure (HF) event or cardiovascular death in patients with HF with mildly reduced or preserved ejection fraction (EF).
Cardiovascular Disease Risk Assessment Using Traditional Risk Factors and Polygenic Risk Scores in the Million Veteran Program
Jason L. Vassy, MD, MPH, MS1,2; Daniel C. Posner, PhD1; Yuk-Lam Ho, MPH1; David R. Gagnon, MD, PhD, MPH1,7; Ashley Galloway, MPH1; Vidisha Tanukonda, MD8; Serena C. Houghton, PhD, MPH1; Ravi K. Madduri, PhD5,13; Benjamin H. McMahon, PhD12; Philip S. Tsao, PhD3,6; Scott M. Damrauer, MD14,16; Christopher J. O’Donnell, MD, MPH1; Themistocles L. Assimes, MD3,4,6; Juan P. Casas, MD, PhD1,2; J. Michael Gaziano, MD, MPH1,11; Michael J. Pencina, PhD15; Yan V. Sun, PhD8,10; Kelly Cho, PhD, MPH1,2; Peter W.F. Wilson, MD8,9,10
doi : 10.1001/jamacardio.2023.0857
Importance Primary prevention of atherosclerotic cardiovascular disease (ASCVD) relies on risk stratification. Genome-wide polygenic risk scores (PRSs) are proposed to improve ASCVD risk estimation.
Skeletal Muscle Mitochondrial Respiration and Exercise Intolerance in Patients With Heart Failure With Preserved Ejection Fraction
Lina Scandalis, PhD1; Dalane W. Kitzman, MD2; Barbara J. Nicklas, PhD3; Mary Lyles, MD3; Peter Brubaker, PhD4; M. Benjamin Nelson, MS2; Michelle Gordon, MS3; John Stone, BS3; Jaclyn Bergstrom, MS1; P. Darrell Neufer, PhD5; Erich Gnaiger, PhD6; Anthony J. A. Molina, PhD1
doi : 10.1001/jamacardio.2023.0957
Importance The pathophysiology of exercise intolerance in patients with heart failure with preserved ejection fraction (HFpEF) remains incompletely understood. Multiple lines of evidence suggest that abnormal skeletal muscle metabolism is a key contributor, but the mechanisms underlying metabolic dysfunction remain unresolved.
Automated Assessment of Cardiac Systolic Function From Coronary Angiograms With Video-Based Artificial Intelligence Algorithms
Robert Avram, MD, MSc1,2,3; Joshua P. Barrios, PhD1,4; Sean Abreau, MS1,4; Cheng Yee Goh, MD3; Zeeshan Ahmed, MD3; Kevin Chung, MD3; Derek Y. So, MD3; Jeffrey E. Olgin, MD1,4; Geoffrey H. Tison, MD, MPH1,4,5
doi : 10.1001/jamacardio.2023.0968
Importance Understanding left ventricular ejection fraction (LVEF) during coronary angiography can assist in disease management.
Vigorous Exercise in Patients With Hypertrophic Cardiomyopathy
Rachel Lampert, MD1; Michael J. Ackerman, MD, PhD2,3,4; Bradley S. Marino, MD5,6; Matthew Burg, PhD1; Barbara Ainsworth, PhD, MPH7; Lisa Salberg8; Maria Teresa Tome Esteban, MD, PhD9; Carolyn Y. Ho, MD10; Roselle Abraham, MD11; Seshadri Balaji, MBBS, PhD12; Cheryl Barth, BS1; Charles I. Berul, MD13,14; Martijn Bos, MD2,3,4; David Cannom, MD15; Lubna Choudhury, MD16; Maryann Concannon, MSW17; Robert Cooper, MD18; Richard J. Czosek, MD19; Anne M. Dubin, MD20; James Dziura, PhD21; Benjamin Eidem, MD22,23; Michael S. Emery, MD24,25; N. A. Mark Estes, MD26,27; Susan P. Etheridge, MD28; Jeffrey B. Geske, MD2; Belinda Gray, MBBS, PhD29; Kevin Hall, MD30; Kimberly G. Harmon, MD31; Cynthia A. James, PhD11; Ashwin K. Lal, MD28; Ian H. Law, MD32; Fangyong Li, MS21; Mark S. Link, MD26,33; William J. McKenna, MD34; Silvana Molossi, MD, PhD35; Brian Olshansky, MD36; Steven R. Ommen, MD2; Elizabeth V. Saarel, MD5,37; Sara Saberi, MD, MS17; Laura Simone, MS21; Gordon Tomaselli, MD11,38; James S. Ware, MD39; Douglas P. Zipes, MD25; Sharlene M. Day, MD17,40; for the LIVE Consortium
doi : 10.1001/jamacardio.2023.1042
Importance Whether vigorous intensity exercise is associated with an increase in risk of ventricular arrhythmias in individuals with hypertrophic cardiomyopathy (HCM) is unknown.
Efficacy and Safety of Low-Dose Triple and Quadruple Combination Pills vs Monotherapy, Usual Care, or Placebo for the Initial Management of Hypertension
Nelson Wang, MD1,2,3; Phidias Rueter, MD2,3; Emily Atkins, PhD1; Ruth Webster, PhD1,4; Mark Huffman, MPH1,5,6; Asita de Silva, PhD7; Clara Chow, PhD1; Anushka Patel, PhD1; Anthony Rodgers, PhD1
doi : 10.1001/jamacardio.2023.0720
Importance Low-dose combination (LDC) antihypertensives consisting of 3 or 4 blood pressure (BP)–lowering drugs have emerged as a potentially important therapy for the initial management of hypertension.
Association Between Intensive vs Standard Blood Pressure Control and Incident Left Ventricular Conduction Disease
Emilie K. Frimodt-Møller, MD1,2; Eric Vittinghoff, PhD1; Gurbani Kaur, MB1; Tor Biering-Sørensen, MD, PhD, MPH2,3; Elsayed Z. Soliman, MD, MSc, MS4; Gregory M. Marcus, MD, MAS1
doi : 10.1001/jamacardio.2023.0845
Importance Left ventricular conduction disease predicts heart failure and death, and the only strategies to mitigate its effects involve implantation of a permanent pacemaker. There are currently no proven preventive strategies for this common condition.
Indication Creep in Transcatheter Aortic Valve Implantation—Data or Desire?
Sachin S. Goel, MD1; Michael J. Reardon, MD2
CRISPR Editing Takes Aim at Ischemia/Reperfusion Injury
Oscar E. Reyes Gaido, BS1; Mark E. Anderson, MD, PhD2
Skeletal Muscle Mitochondrial Dysfunction and Exercise Intolerance in Heart Failure With Preserved Ejection Fraction
Ambarish Pandey, MD, MSCS1; Neil Keshvani, MD1; Windy Alonso, PhD, RN2
Acute Respiratory Distress Following Percutaneous Coronary Intervention of Osteal Occlusion of Left Main Coronary Artery
Mochamad Yusuf Alsagaff, MD, PhD1; Makyhan Jibril Al Farabi, MD1; Arief Bakhtiar, MD2
A Woman With Syncope and Frequent Premature Ventricular Contractions
Mazen M. Kawji, MD1,2
A Woman With Recurrent Syncope and Malar Flush in the Setting of a Left Atrial Echogenic Mass
Zhenyu Dong, MD, PhD1,2; Yanmei Lu, MD, PhD1,2; Baopeng Tang, MD, PhD1,2
Young Man With Coarctation of the Aorta
Luis David Beltran Ontiveros, MD1; Juan Francisco Fritche Salazar, MD1; Hugo Rodriguez Zanella, MD1
How Do We Credit the Evidence Generated From Subgroup Analyses in Randomized Clinical Trials?
Yinchu Cheng, PhD1,2; Na He, PhD1,2; Yingying Yan, PhD1,2
How Do We Credit the Evidence Generated From Subgroup Analyses in Randomized Clinical Trials?—Reply
Mark A. Hlatky, MD1; Neil J. Stone, MD2; JoAnn E. Manson, MD, ScD3
